Neurogene Inc. (NASDAQ:NGNE – Get Free Report) CFO Christine Mikail Cvijic sold 4,061 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $34.82, for a total transaction of $141,404.02. Following the completion of the transaction, the chief financial officer owned 88,840 shares in the company, valued at approximately $3,093,408.80. The trade was a 4.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Christine Mikail Cvijic also recently made the following trade(s):
- On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The stock was sold at an average price of $34.06, for a total value of $25,170.34.
- On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total value of $300,000.00.
Neurogene Stock Performance
Shares of NASDAQ:NGNE traded up $1.46 during midday trading on Thursday, reaching $35.34. The company’s stock had a trading volume of 363,205 shares, compared to its average volume of 174,652. Neurogene Inc. has a fifty-two week low of $15.93 and a fifty-two week high of $37.27. The firm has a 50 day moving average price of $29.05 and a two-hundred day moving average price of $23.14. The firm has a market capitalization of $558.37 million, a price-to-earnings ratio of -7.77 and a beta of 1.68.
Institutional Investors Weigh In On Neurogene
Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its stake in Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after acquiring an additional 978 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Neurogene by 24.7% in the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock valued at $88,000 after purchasing an additional 1,000 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Neurogene by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock valued at $531,000 after purchasing an additional 1,008 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Neurogene by 12.8% during the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after purchasing an additional 2,950 shares during the last quarter. Institutional investors own 52.37% of the company’s stock.
Analyst Ratings Changes
A number of research analysts recently issued reports on NGNE shares. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Neurogene in a research report on Tuesday, June 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a report on Tuesday, April 21st. Rodman & Renshaw started coverage on shares of Neurogene in a research report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price objective on the stock. UBS Group set a $70.00 target price on Neurogene in a research report on Wednesday, June 3rd. Finally, Guggenheim started coverage on Neurogene in a research note on Tuesday, April 28th. They set a “buy” rating and a $69.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $84.83.
Get Our Latest Stock Analysis on NGNE
About Neurogene
Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.
Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.
Featured Stories
- Five stocks we like better than Neurogene
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
